Abstract:OBJECTIVE:To explore clinical and muscular pathological features of statin-induced myopathy.METHODS:Nine patients were enrolled in this study, who were diagnosed as statin-induced myopathy by muscle biopsy in Peking University First Hospital from April, 2012 to October, 2014. The clinical data and pathological findings were analyzed.RESULTS:The exposure time to statins varied from 4 days to 4 years in the total of 9 patients, 6 males and 3 females, with the average age of 63 ± 6 (55 to 74) years old. Three patients suffered from myalgia and 6 patients complained of weakness mainly at the proximal limbs, while no symptoms occured in 3 patients. Serum creatine kinase (CK) increased in all patients with the maximum value varied from 468 to 8 000 U/L. Serum myositis antibodies were tested in 7 patients and all were negative. Electromyogram was performed in six patients with myogenic damage found in 2 patients. MRI of bilateral thigh muscle was carried out in six patients with muscle edema and mild fatty infiltration found in 2 patients. All patients underwent skeletal muscle biopsy with histochemical and immunohistochemical staining. The main muscular pathological features were muscle fiber atrophy, necrosis, regeneration and increased lipid droplets. Ragged blue fiber, cytochrome C oxidase-negative muscle fibers and decreased NADH activity were observed in some patients. MHC-I expressed in the sarcolemma of muscle fibers at various levels. Mild C5b-9 staining was found in the endomysium, capillary and cytoplasm. Symptoms and the level of CK were improved in 7 patients after discontinuing statins or changing to another statin, while the immunosuppressive therapy were used in 2 patients and shown to be effective.CONCLUSIONS:Statin induced myopathy is self-limiting in most patients, with improvement after discontinuation of statins. Few patients with autoimmune necrotic myopathy need immunosuppressive therapy.

Atorvastatin-Induced Necrotizing Myopathy and its Response to Combination Therapy

Statin-induced debilitating weakness and myopathy

An atorvastatin‐induced positive anti‐HMGCR immune‐mediated necrotizing myopathy case

Immune-Mediated Necrotizing Myopathy Manifesting after Five Years of Statin Therapy

Statin-Induced Autoimmune Myopathy: A Diagnostic Challenge in Muscle Weakness

Statin-induced immune-mediated necrotizing myopathy with concomitant increase of anti-HMGCR and anti-ACHR antibodies

Rosuvastatin-Induced Myopathy: A Case Series

[The Clinical and Muscular Pathological Features of Statin-Induced Myopathy].

A Case of Statin-Associated Autoimmune Myopathy: Management and Treatment

High-Intensity Statin Therapy and Associated Rhabdomyolysis in Chronic Liver Disease: A Case Report and Review of Literature

High-dose atorvastatin therapy progressively decreases skeletal muscle mitochondrial respiratory capacity in humans

Refractory Statin-Induced Immune-Mediated Necrotizing Myositis: Challenges and Perils in Its Management

The Role of Mitochondria in Statin-Induced Myopathy

Rhabdomyolysis due to warfarin and atorvastatin combination therapy in a patient with ischemic heart disease: (A drug interaction)

Statin-Induced Increases in Atrophy Gene Expression Occur Independently of Changes in PGC1α Protein and Mitochondrial Content

Statin-associated muscle symptoms: A comprehensive exploration of epidemiology, pathophysiology, diagnosis, and clinical management strategies

Simvastatin Enhances Muscle Regeneration Through Autophagic Defect-Mediated Inflammation and mTOR Activation in G93ASOD1 Mice

A Neuropathy Mimic: Statin-Induced Myopathy Presenting as Guillain-Barré Syndrome

Favorable Response in Statin-Naive Paraneoplastic Anti-HMGCR Antibody-Associated Myopathy to Single Dose of Rituximab and Persistent Remission With Management of Underlying Lung Cancer

Statin-associated myasthenic weakness

Dysfunctional endocannabinoid CB1 receptor expression and signaling contribute to skeletal muscle cell toxicity induced by simvastatin